Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...
Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...
Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported ...
Moderna is working with Merck to develop a cancer vaccine. Moderna also recently inked a supply deal for its Covid ...